Information Provided By: 
Fly News Breaks for March 31, 2016
GNCA
Mar 31, 2016 | 14:14 EDT
Cowen analyst Phil Nadeau said Genocea reported positive 12 month data from the Phase II dose optimization trial of GEN-003 in genital herpes. The data suggests that vaccination with GEN-003 is as effective as daily antiviral therapy at preventing the recurrence of lesions through 12 months. The analyst believes GEN-003 has a greater than $700M sales potential and that Genocea is "significantly undervalued." Nadeau rates Genocea an Outperform with a $40 price target.
News For GNCA From the Last 2 Days
There are no results for your query GNCA
